HRAS and gonorrhea: We have previously shown that approximately 60% ER-positive AMEs harbor PIK3CA or AKT1 mutations, whereas up to 60% of ER-negative AMEs are characterized by HRAS Q61 mutations concurrent with mutations affecting genes of the PI3K signaling pathway.3 Given the occasional histologic similarities between AMEs and PAs, and the fact that a subset of AMEs lack a known driver genetic alteration in the form of somatic mutations affecting protein coding genes, we posited that a subset of AMEs may harbor oncogenic fusion genes previously described in other myoepithelial lesions including PAs.